Aktis Oncology has a $500M enterprise value, cash to last 3+ years, and initial clinical data coming in Q1 2027. If one program hits, the company could be worth $10 billion — or get acquired by Lilly, which backstopped its IPO with $100M. The moat: China can't replicate actinium-based radiopharmaceuticals.